INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.3500
-0.4500 (-9.38%)
At close: 4:00PM EST

4.44 +0.09 (2.04%)
After hours: 4:11PM EST

Stock chart is not supported by your current browser
Previous Close4.8000
Open4.9500
Bid4.12 x 46000
Ask4.37 x 800
Day's Range4.2005 - 4.9500
52 Week Range4.2005 - 14.0000
Volume983,183
Avg. Volume523,442
Market Cap323.073M
Beta (3Y Monthly)2.77
PE Ratio (TTM)N/A
EPS (TTM)-1.71
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.40
Trade prices are not sourced from all markets
  • Muddy Waters Research founder Carson Block talks morality shorts
    Yahoo Finance Video15 days ago

    Muddy Waters Research founder Carson Block talks morality shorts

    Carson Block, muddy waters research founder, talks morality shorts and the opioid crisis

  • Reuters1 hour ago

    New Hampshire physician assistant guilty of Insys opioid kickback scheme

    A federal jury in Concord, New Hampshire, found Christopher Clough, 45, guilty of all charges he faced in a case that stemmed from a years-long investigation into the Arizona company's efforts to promote its opioid medication Subsys. Patrick Richard, Clough's lawyer, said he is evaluating his options, including an appeal. The verdict came a month before six former Insys executives and managers including John Kapoor, a onetime billionaire who was its founder and chairman, face trial on charges that they conspired to bribe medical practitioners to prescribe Subsys.

  • Reuters2 hours ago

    New Hampshire physician assistant guilty of Insys opioid kickback scheme

    A former physician assistant in New Hampshire was convicted on Tuesday of charges that he accepted nearly $50,000 in kickbacks from Insys Therapeutics Inc in exchange for prescribing its addictive fentanyl spray. A federal jury in Concord, New Hampshire, found Christopher Clough, 45, guilty of all charges he faced in a case that stemmed from a years-long investigation into the Arizona company's efforts to promote its opioid medication Subsys. Patrick Richard, Clough's lawyer, said he is evaluating his options, including an appeal.

  • Market Exclusive8 hours ago

    INSYS announces Progress on Spray Technology Products, CBD Pharmaceuticals

    INSYS Therapeutics, Inc. (NASDAQ:INSY) has today given information on the progress of their product pipeline that includes CBD oral solution and naloxone and epinephrine nasal sprays. According to the company president and CEO, Saeed Motahari, the strategic change of moving away from opioids to the production of new drug delivery systems and CBD pharmaceuticals is […] The post INSYS announces Progress on Spray Technology Products, CBD Pharmaceuticals appeared first on Market Exclusive.

  • GlobeNewswire10 hours ago

    INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that Dr. Dean Mariano, senior director, clinical development and medical affairs at INSYS, presented during the first day of the U.S. Food and Drug Administration’s (FDA) Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting being held Dec. 17 and 18, 2018.

  • GlobeNewswireyesterday

    INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology

    INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today provided an update on its product pipeline, which includes cannabidiol (CBD) oral solution as well as epinephrine and naloxone nasal sprays. “Our strategic shift in focus away from opioids and to pharmaceutical-grade cannabinoids and novel drug delivery systems continues to gain momentum and has been driven by our strong commitment to advancing our diverse product pipeline,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics.

  • Surprise! The Largest U.S. Pension Fund Just Bought These 2 Marijuana Stocks
    Motley Fool2 days ago

    Surprise! The Largest U.S. Pension Fund Just Bought These 2 Marijuana Stocks

    And you might scratch your head over the pension fund's picks.

  • Reuters6 days ago

    Opioid maker Insys paid kickbacks to physician assistant, jury hears

    A former Insys Therapeutics Inc sales representative now married to the drugmaker's ex-CEO said on Wednesday she arranged to have a physician assistant in New Hampshire receive kickbacks to prescribe patients its addictive fentanyl spray. The testimony came at the start of the trial in federal court in Concord, New Hampshire, of Christopher Clough, a physician assistant who prosecutors say accepted nearly $50,000 from Insys in exchange for prescribing its powerful opioid pain drug, Subsys. The trial could provide a glimpse into some of the evidence prosecutors will use in next month's trial of six former Insys executives and managers, including John Kapoor, a onetime billionaire who was the company's founder and chairman.

  • Reuters6 days ago

    Opioid maker Insys paid physician assistant kickbacks, U.S. jury hears

    A former physician assistant in New Hampshire put his own greed ahead of medical obligations by taking kickbacks from Insys Therapeutics Inc to prescribe patients its highly addictive fentanyl spray, a federal prosecutor said on Wednesday. Assistant U.S. Attorney Seth Aframe told a federal jury in Concord, New Hampshire, at the start of a trial that the kickbacks to Christopher Clough, 45, were part of the Arizona drugmaker's overall effort to boost sales of its opioid, Subsys.

  • Reuters6 days ago

    Physician assistant faces U.S. trial over Insys opioid kickbacks

    A former physician assistant is set to face trial in New Hampshire on Wednesday over charges he accepted kickbacks from Insys Therapeutics Inc to prescribe a highly addictive fentanyl spray the drugmaker produced. A federal jury in Concord, New Hampshire, will hear opening statements in the trial of Christopher Clough, whose case could provide a glimpse into some of the evidence prosecutors plan to use in the upcoming trial of six former Insys executives and managers. Both cases stem from what prosecutors say was a wide-ranging scheme overseen by Insys executives including John Kapoor, a onetime billionaire who was its founder and chairman, to pay medical practitioners kickbacks to prescribe its powerful opioid, Subsys.

  • ACCESSWIRE8 days ago

    Alternatives to Watch

    HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Below are several companies positioning themselves to be a viable opioid alternative. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), INSYS Therapeutics, ...

  • GlobeNewswire12 days ago

    Detailed Research: Economic Perspectives on AT&T, JD, EMC Insurance Group, Insys Therapeutics, Medidata Solutions, and Heritage-Crystal Clean — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • These 17 Pot Stocks Were Throttled in November
    Motley Fool13 days ago

    These 17 Pot Stocks Were Throttled in November

    Forget seeing green! Investors in these 17 marijuana stocks were treated to double-digit-percentage losses last month.

  • INSYS Therapeutics Inc (NASDAQ:INSY): Time For A Financial Health Check
    Simply Wall St.14 days ago

    INSYS Therapeutics Inc (NASDAQ:INSY): Time For A Financial Health Check

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like INSYS Therapeutics Inc (NASDAQ:INSY), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • GlobeNewswire14 days ago

    INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

    PHOENIX, Dec. 04, 2018 -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and.

  • Reuters20 days ago

    Former Insys executive pleads guilty to opioid bribe scheme

    A former executive at Insys Therapeutics Inc (INSY.O) pleaded guilty on Wednesday to participating in a scheme to bribe doctors to prescribe the company's powerful opioid medication and entered into a deal to cooperate with prosecutors. Alec Burlakoff, who was the Arizona-based drugmaker's vice president of sales, pleaded guilty in federal court in Boston to racketeering conspiracy, becoming the highest level executive to admit wrongdoing in the investigation of Insys. By agreeing to cooperate, Burlakoff could become a key witness at the January trial of six former Insys executives and managers charged with engaging in the scheme, including the company's billionaire founder, John Kapoor.

  • Reuters20 days ago

    Former Insys executive pleads guilty to opioid bribe scheme

    A former executive at Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a scheme to bribe doctors to prescribe the company's powerful opioid medication and entered into a deal to cooperate with prosecutors. Alec Burlakoff, who was the Arizona-based drugmaker's vice president of sales, pleaded guilty in federal court in Boston to racketeering conspiracy, becoming the highest level executive to admit wrongdoing in the investigation of Insys. By agreeing to cooperate, Burlakoff could become a key witness at the January trial of six former Insys executives and managers charged with engaging in the scheme, including the company's billionaire founder, John Kapoor.

  • Associated Press20 days ago

    Ex-executive to cooperate with feds in opioid kickback case

    BOSTON (AP) — A former opioid sales executive admitted Wednesday to participating in a nationwide conspiracy to bribe doctors to prescribe a highly addictive fentanyl spray for people who didn't need it and will cooperate with prosecutors targeting his co-workers in the closely watched case against Insys Therapeutics.

  • Reuters20 days ago

    Former Insys executive pleads guilty to opioid bribe scheme

    A former executive at Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a scheme to bribe doctors to prescribe the company's powerful opioid medication and entered into a deal to cooperate with prosecutors. Alec Burlakoff, who was the Arizona-based drugmaker's vice president of sales, pleaded guilty in federal court in Boston to racketeering conspiracy, becoming the highest-level executive to admit wrongdoing in the investigation of Insys. By agreeing to cooperate, Burlakoff could become a key witness at the January trial of six former Insys executives and managers charged with engaging in the scheme, including the company's billionaire founder, John Kapoor.

  • Reuters20 days ago

    Former Insys executive pleads guilty to opioid bribe scheme

    A former executive at Insys Therapeutics Inc pleaded guilty on Wednesday to participating in a scheme to bribe doctors to prescribe the company's powerful opioid medication and entered into a deal to cooperate with prosecutors. Alec Burlakoff, who was the Arizona-based drugmaker's vice president of sales, pleaded guilty in federal court in Boston to racketeering conspiracy, becoming the highest-level executive to admit wrongdoing in the investigation of Insys. By agreeing to cooperate, Burlakoff could become a key witness at the January trial of six former Insys executives and managers charged with engaging in the scheme, including the company's billionaire founder, John Kapoor.

  • 3 Marijuana Stocks to Avoid Like the Plague in December
    Motley Fool20 days ago

    3 Marijuana Stocks to Avoid Like the Plague in December

    This isn't the type of buzz investors are looking for.

  • Reuters20 days ago

    Former executive at opioid maker Insys to plead guilty

    A former executive at Insys Therapeutics Inc is expected to plead guilty on Wednesday to charges that he participated in a scheme to bribe doctors to prescribe the company's opioid drug. Alec Burlakoff, who was the Chandler, Arizona-based drugmaker's former vice president of sales, is expected to appear in federal court in Boston after being previously charged with engaging in a racketeering scheme with others at Insys. Prosecutors in a court filing earlier this month confirmed they had reached a plea deal with Burlakoff, 44, but did not say whether as part of the agreement he would become a cooperating witness in their case.

  • ACCESSWIRE21 days ago

    Cannabis Stocks That Could Uptrend

    HENDERSON, NV / ACCESSWIRE / November 27, 2018 / The cannabis sector certainly took a hit in recent weeks, however, not all cannabis stocks have been affected. Here's a couple that still warrant your attention. ...

  • Why Marijuana Stock INSYS Therapeutics Is Down 30% in 2018
    Motley Fool27 days ago

    Why Marijuana Stock INSYS Therapeutics Is Down 30% in 2018

    It's been a wild year for the drug company.

  • It's Time to Throw This Marijuana Stock Away and Never Look Back
    Motley Fool27 days ago

    It's Time to Throw This Marijuana Stock Away and Never Look Back

    This pot stock is a disaster, and it belongs nowhere near investors' portfolios.